Japan’s Generic Industry Likely To Reorganize Into Two To Three Sizable Companies – JGPMA President
This article was originally published in PharmAsia News
Japan Generic Pharmaceutical Manufacturers Association President Hiroyuki Sawai told a July 3 meeting that as competition heats up in Japan, the generics industry needs to reorganize to boost capital and increase scale. Sawai estimated that through mergers and acquisitions, the 44 current generics drug makers in Japan may be reduced to two to three major players in the future. Sawai is also president of Sawai Pharmaceuticals, the biggest generics drug maker in Japan, but ranked 33 in the world. Generics in Japan account for 17 percent of the drug market, a low level compared to nearly 50 percent in the U.S. and Europe. (Click here for more - Japanese language
You may also be interested in...
Given its ever-growing role as a critical component of the global biopharma industry, you can’t afford not to be up to speed on Asia. This biweekly selection of insights from our experienced on-the-ground team will help.
Becton Dickinson will spend $1.2bn over the next four years to improve its drug-delivery device manufacturing capabilities. See what Eric Borin, president of BD, said about it here.
Pfizer is producing vaccine doses at scale now that it has buttoned down the manufacturing process.